Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients

Inclusion Criteria: * Histologically or cytologically confirmed breast adenocarcinoma. * Within 20-45 days after the surgical excision of the primary tumor with tumor-free operation margins; at least 10 axillary lymph nodes have to be removed. * Absence of lymph node involvement after eclosion and hormone (E\&H) staining and light microscopy evaluation. * Premenopausal or postmenopausal women with at least one of the following tumor characteristics is required in order to characterize the tumor as high risk: * Estrogen receptor (ER) (-) and progesterone receptor (PR)(-); * Ki-67 + \> 30%; Grade III; HER2 (3+) (after an amendment on 15.05.2008 women with HER2 (3+) were not included); Perineural infiltration or presence of tumor emboli in blood or lymph vessels. * Postmenopausal women with tumors 1-2 cm are eligible if the tumor has at least 2 of the above mentioned high risk criteria. * Premenopausal and postmenopausal women with tumors measuring \> 2 cm are eligible irrespectively of the expression of the above adverse prognostic tumor criteria. * Absence of any clinical or radiological evidence of local or metastatic disease. * Age \> 18 years. * Performance status (WHO) \< 3. * Adequate bone marrow function (absolute neutrophil count \> 1000/mm\^3, platelet count \> 100000/mm\^3, hemoglobin \> 9 gr/mm\^3). * Adequate liver (bilirubin \< 1.5 times upper limit of normal and SGOT/SGPT \< 2 times upper limit of normal) and renal function (creatinine \< 2 mg/dl). * Adequate cardiac function (LVEF \> 50%). * Negative pregnancy test. * Informed consent. Exclusion Criteria: * Other invasive malignancy within the past 5 years except nonmelanoma skin cancer. * Other concurrent uncontrolled illness that could affect compliance with the study. * Psychiatric illness or social situation that would preclude study compliance. * Pregnant or nursing women. * History of allergic reaction attributed to docetaxel. * Other concurrent investigational agents.